In addition, as shown in Figure 1C, the inhibitory effect of proxalutamide on PCa cell migration was significantly stronger than that of enzalutamide (the second-generation clinical AR antagonist with the same core structure as proxalutamide). The gene discussed is AR; the disease is posterior cortical atrophy.